Panobinostat for the treatment of multiple myeloma (Q37992104)

26 August 2017

title

Panobinostat for the treatment of multiple myeloma. (English)

1 reference

26 August 2017

Sagar Lonial

1 reference

26 August 2017

Paola Neri

1 reference

26 August 2017

Nizar J Bahlis

series ordinal

1 reference

26 August 2017

language of work or name

English

0 references

publication date

12 March 2012

1 reference

Expert Opinion on Investigational Drugs

26 August 2017

published in

1 reference

26 August 2017

1 reference

26 August 2017

1 reference

26 August 2017

page(s)

733-747

1 reference

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

The epigenomics of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

Histone deacetylases, transcriptional control, and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

Chromatin modifications and their function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

HDAC inhibitors: clinical update and mechanism-based potential.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

The human histone deacetylase family

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

Simple histone acetylation plays a complex role in the regulation of gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

Targeting histone deacetylase in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

Anticancer activities of histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

Histone deacetylases and transcriptional therapy with their inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

Histone deacetylase inhibitors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

The Sir2 family of protein deacetylases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

Activation of p53 Sequence-Specific DNA Binding by Acetylation of the p53 C-Terminal Domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

Regulation of E2F1 activity by acetylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

The c-MYC oncoprotein is a substrate of the acetyltransferases hGCN5/PCAF and TIP60

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

Acetylation and deacetylation of non-histone proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

Role of the aggresome pathway in cancer: targeting histone deacetylase 6-dependent protein degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

HDAC6 and microtubules are required for autophagic degradation of aggregated huntingtin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

Intracellular protein degradation and its therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

Histone deacetylases and cancer: causes and therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

Histone deacetylase inhibitors: Potential in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

Discovery and development of SAHA as an anticancer agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

Bmf is a possible mediator in histone deacetylase inhibitors FK228 and CBHA-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

Histone deacetylase inhibitor FK228 inhibits tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

Suberoylanilide hydroxamic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing nuclear factor-kappaB activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

Effects of histone deacetylase inhibitors on HIF-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

Histone deacetylase inhibitors modulate metalloproteinase gene expression in chondrocytes and block cartilage resorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

Induction of osteogenic differentiation of human mesenchymal stem cells by histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

Histone deacetylase inhibitors promote osteoblast maturation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

Histone deacetylase 1-mediated histone modification regulates osteoblast differentiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

Inhibitors of histone deacetylases in class I and class II suppress human osteoclasts in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

Inhibition of histone deacetylase suppresses osteoclastogenesis and bone destruction by inducing IFN-beta production

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

Essential role of BETA2/NeuroD1 in development of the vestibular and auditory systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

Role of checkpoint kinase 1 (Chk1) in the mechanisms of resistance to histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

Histone deacetylase inhibitors increase p21(WAF1) and induce apoptosis of human myeloma cell lines independent of decreased IL-6 receptor expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

Molecular sequelae of histone deacetylase inhibition in human malignant B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

Analysis of histone deacetylase inhibitor, depsipeptide (FR901228), effect on multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

KD5170, a novel mercaptoketone-based histone deacetylase inhibitor, exerts antimyeloma effects by DNA damage and mitochondrial signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

Valproic acid exerts anti-tumor as well as anti-angiogenic effects on myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

Vascular risk assessment in patients with sickle cell disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

Chemical phylogenetics of histone deacetylases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph- acute lymphoblastic leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

HDAC inhibition by LBH589 affects the phenotype and function of human myeloid dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

Dual degradation of aurora A and B kinases by the histone deacetylase inhibitor LBH589 induces G2-M arrest and apoptosis of renal cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

Experimental treatment of pancreatic cancer with two novel histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

Transcriptional control at regulatory checkpoints by histone deacetylases: molecular connections between cancer and chromatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

Histone deacetylase inhibitors in cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

Histone deacetylases and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

Deacetylation of p53 modulates its effect on cell growth and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

Multiple myeloma: biology of the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.668883

10.1517/13543784.2012.668883

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference